TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
BioInvent International AB
Closing information (x1000 SEK)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover |
71,461
|
326,126
|
19,384 |
Financial expenses |
1,528
|
794
|
717 |
Earnings before taxes |
-330,100
|
-42,503
|
-278,444 |
EBITDA |
-369,942
|
-50,921
|
-278,350 |
Total assets |
1,400,180
|
1,712,214
|
1,447,311 |
Current assets |
1,133,265
|
1,084,062
|
1,116,019 |
Current liabilities |
75,918
|
87,319
|
58,792 |
Equity capital |
1,309,727
|
1,606,122
|
1,366,987 |
- share capital |
13,161
|
12,994
|
11,694 |
Employees (average) |
104
|
89
|
79 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency |
93.5%
|
93.8%
|
94.5% |
Turnover per employee |
687
|
3,664
|
245 |
Profit as a percentage of turnover |
-461.9%
|
-13.0%
|
-1436.5% |
Return on assets (ROA) |
-23.5%
|
-2.4%
|
-19.2% |
Current ratio |
1492.7%
|
1241.5%
|
1898.2% |
Return on equity (ROE) |
-25.2%
|
-2.6%
|
-20.4% |
Change turnover |
-254,665
|
306,742
|
-127,988 |
Change turnover % |
-78%
|
1582%
|
-87% |
Chg. No. of employees |
15
|
10
|
7 |
Chg. No. of employees % |
17%
|
13%
|
10% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.